Consensus InMode Ltd. Deutsche Boerse AG

Stocks

154 IL0011595993

Advanced Medical Equipment & Technology

Real-time Estimate Tradegate 08:10:17 2026-09-18 EDT			5-day change	1st Jan Change
12.65 ^EUR	+0.34%		-0.60%	+1.01%

09-14	M.N. Business Strategy, Ltd. cancelled the acquisition of remaining shares InMode Ltd..	CI
09-09	InMode Ltd. Announces Launch Of Morpheus8 Cool On Morpheus8MAX Platform	CI

f05099d04.KBHX5LbYOLDpaUF2AXeGKDmVsm3lFSwFNQE6QW8D0Qk.bCeBifuJboi9WzI-bB_yXHDsgwapX0hJeU4IEjgy4kAcQO7U0Y5g4LkgdQ~fa715a4919c29ceb84da38d6c60347e6

Analysts' recommendations: InMode Ltd.

06-25	Alert tagged to multiple companies from a research report withdrawn	RE
25-07-30	InMode Q2 revenue misses estimates	RE
25-04-29	UBS Adjusts InMode Price Target to $16.25 From $19, Maintains Neutral Rating	MT
25-04-29	BTIG Research Downgrades InMode to Neutral From Buy	MT
25-04-28	Baird Downgrades InMode to Neutral From Outperform, $16 Price Target; Shares Fall	MT
25-04-14	InMode Unlikely to Meet Street Consensus for Q1 Non-GAAP EPS, Needham Says	MT
25-01-09	Barclays Adjusts Price Target on InMode to $26 From $27, Maintains Overweight Rating	MT
24-11-01	UBS Adjusts Price Target on InMode to $19 From $17, Maintains Neutral Rating	MT
24-10-17	BTIG Initiates InMode at Buy With $25 Price Target	MT
24-10-10	UBS Adjusts Price Target on InMode to $17 From $20, Maintains Neutral Rating	MT
24-07-23	Jefferies Downgrades InMode to Hold From Buy, Adjusts Price Target to $19 From $21	MT
24-07-15	Barclays Lowers Price Target on InMode to $29 From $33, Maintains Overweight Rating	MT
24-07-12	Canaccord Genuity Adjusts InMode's PT to $16 From $21, Keeps Hold Rating	MT
24-05-03	UBS Adjusts Price Target on InMode to $20 From $26, Maintains Neutral Rating	MT
24-04-12	Barclays Adjusts Price Target on InMode to $33 From $34, Maintains Overweight Rating	MT
24-02-15	Barclays Adjusts Price Target on InMode to $34 From $32, Maintains Overweight Rating	MT
24-02-14	UBS Adjusts InMode Price Target to $26 From $24, Maintains Neutral Rating	MT
24-01-18	Barclays Trims Price Target on InMode to $32 From $33, Maintains Overweight Rating	MT
23-11-03	UBS Downgrades InMode to Neutral From Buy, Cuts Price Target to $24 From $52	MT
23-08-01	Barclays Adjusts Price Target on InMode to $54 From $47, Maintains Overweight Rating	MT
23-07-28	UBS Adjusts InMode Price Target to $52 From $48, Maintains Buy Rating	MT
23-07-28	Baird Adjusts Price Target on InMode to $61 From $53, Maintains Outperform Rating	MT
23-05-04	Barclays Adjusts Price Target on InMode to $47 From $45, Maintains Overweight Rating	MT
23-03-29	UBS Initiates Coverage on InMode With Buy Rating, $40 Price Target	MT
23-02-17	Needham Downgrades InMode to Hold From Buy as Q1 Aesthetics Patient Survey Shows Consumers Cutting Spending on Procedures	MT

More recommendations

Other Advanced Medical Equipment & Technology

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
INMODE LTD.	-	-	-	-
THERMO FISHER SCIENTIFIC, INC.				-2%
DANAHER CORPORATION				+7.81%
INTUITIVE SURGICAL, INC.				+24.2%
BOSTON SCIENTIFIC CORPORATION				+41.81%
EDWARDS LIFESCIENCES CORPORATION				+14.4%
SIEMENS HEALTHINEERS AG				+18.48%
AGILENT TECHNOLOGIES, INC.				+11.91%
WATERS CORPORATION				+3.02%
ILLUMINA, INC.				-17.35%
Average				+11.36%
Weighted average by Cap.				+10.12%